NCT03595059CompletedPhase 1
A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Sept 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- First submitted
- 28 Jun 2024
- Start date
- 15 Mar 2021
- Lead sponsor
- AbbVie Deutschland GmbH & Co. KG
- Diseases
- Lung cancer
- NCT number
- NCT03595059
- EU CT number
- 2024-513625-23-00
- EudraCT number
- 2020-002495-12
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 1
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.